Technology 96 of 266
Viral vectors
6 EIC Accelerator winners build on Viral vectors, 1% of the classified companies, in 1 sector and 1 industry.
6
Companies
1
Sectors
1
Industries
5
Countries
0%
Exits
33%
Show signs of scaling
Sectors
- Health6 (100%)
Industries
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Viral vectors
Show the numbers
| Companies | Viral vectors | |
|---|---|---|
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 2 | 2 |
| 2022 | 1 | 1 |
| 2023 | 1 | 1 |
| 2024 | 1 | 1 |
What happened to them (6 of 6 checked)
- Active5 (83%)
- Exit0 (0%)
- Failed1 (17%)
- Other0 (0%)
Signs of scaling
- Scaling2 (33%)
- Not scaling2 (33%)
- Scaling unclear2 (33%)
Countries
Keywords
- Adeno-associated virus
- Anti-angiogenesis
- Cancer vaccines
- Cone protection
- DiGeorge syndrome
- Endogenous retroviruses
- Immunotherapy resistance
- Limb-girdle muscular dystrophy
- Melanoma
- Oncology
- Oncolytic viruses
- Ophthalmology
- Orphan drugs
- Ovarian cancer
- Rare diseases
- Retinitis pigmentosa
- Severe combined immunodeficiency
- Solid tumours
- Thymus regeneration
All 6 companies using Viral vectors
| Company | Project | Industry | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|---|
| Atamyo Therapeutics | ATA-100Smart, organotropic gene therapy designed for optimised efficacy, patient safety and affordability to treat limb-girdle muscular dystrophy-R9 | Biopharmaceuticals | France | March 2024 | Blended finance | Active | Deep dive |
| Genewity B.V. | i-THYMUSThe i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system | Biopharmaceuticals | Netherlands | March 2023 | Grant first | Active | Deep dive |
| TILT BIOTHERAPEUTICS OY | I-CREATEFighting cancer with next generation oncolytic immunotherapy in ovarian, head & neck, and lung cancers (Immune Checkpoint Response Enabling Adenovirus Technology ) | Biopharmaceuticals | Finland | March 2022, March 2024 | Blended finance | Active | Deep dive |
| Vascular Biogenics LTD | OVALThe OVAL study for VB-111 treatment of platinum-resistant ovarian cancer | Biopharmaceuticals | Israel | October 2021 | Blended finance | Insolvent | Deep dive |
| InProTher ApS | CancERVaccTargeting Cancer with ERV Vaccines | Biopharmaceuticals | Denmark | June 2021 | Blended finance | Active | Deep dive |
| SparingVision SAS | SIROCOSparing gene therapy for Inherited ROd COne dystrophies | Biopharmaceuticals | France | April 2019 | Grant only | Active | Deep dive |